• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies.

作者信息

Jakovljevic Mihajlo, Yamada Tetsuji

机构信息

Global Health Economics and Policy, Faculty of Medical Sciences, University of KragujevacKragujevac, Serbia.

Center for Health Trends and Forecasts, Institute for Health Metrics and Evaluation, University of WashingtonSeattle, WA, United States.

出版信息

Front Pharmacol. 2017 Sep 21;8:662. doi: 10.3389/fphar.2017.00662. eCollection 2017.

DOI:10.3389/fphar.2017.00662
PMID:28983250
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5613116/
Abstract
摘要

相似文献

1
Editorial: Role of Health Economic Data in Policy Making and Reimbursement of New Medical Technologies.社论：卫生经济数据在新医疗技术政策制定和报销中的作用。
Front Pharmacol. 2017 Sep 21;8:662. doi: 10.3389/fphar.2017.00662. eCollection 2017.
2
Health Economic Data in Reimbursement of New Medical Technologies: Importance of the Socio-Economic Burden as a Decision-Making Criterion.新型医疗技术报销中的卫生经济数据：社会经济负担作为决策标准的重要性
Front Pharmacol. 2016 Aug 17;7:252. doi: 10.3389/fphar.2016.00252. eCollection 2016.
3
Editorial: Role of health economic data in policy making and reimbursement of new medical technologies, Volume II.社论：健康经济数据在新医疗技术政策制定与报销中的作用，第二卷。
Front Public Health. 2023 Mar 27;11:1179300. doi: 10.3389/fpubh.2023.1179300. eCollection 2023.
4
Introduction to health economics and decision-making: Is economics relevant for the frontline clinician?健康经济学与决策导论：经济学对于一线临床医生而言是否重要？
Best Pract Res Clin Gastroenterol. 2013 Dec;27(6):831-44. doi: 10.1016/j.bpg.2013.08.016. Epub 2013 Sep 26.
5
[HEALTH ECONOMIC ANALYSIS AND FAIR DECISION MAKING].[健康经济分析与公平决策]
Rev Prat. 2015 Sep;65(7):909-11.
6
Utilization of health technologies-Do not look where there is a light; shine your light where there is a need to look! Relating national health goals with resource allocation decision-making; illustration through examining the Israeli healthcare system.卫生技术利用——不要在有光的地方寻找；要在需要寻找的地方发光！将国家卫生目标与资源分配决策联系起来；通过考察以色列医疗保健系统来说明。
Health Policy. 2009 Oct;92(2-3):268-75. doi: 10.1016/j.healthpol.2009.04.003. Epub 2009 May 31.
7
Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom.经济评估指南能否提高资源配置效率？以葡萄牙、荷兰、芬兰和英国为例。
Int J Technol Assess Health Care. 2000 Autumn;16(4):1179-92. doi: 10.1017/s0266462300103216.
8
Health technology assessment (HTA): a brief introduction of history and the current status in the field of cardiology under the economic crisis.健康技术评估（HTA）：经济危机下心脏病学领域的历史和现状简介。
J Evid Based Med. 2015 Aug;8(3):161-4. doi: 10.1111/jebm.12171.
9
Reimbursement decisions in health policy--extending our understanding of the elements of decision-making.卫生政策中的报销决策——拓展我们对决策要素的理解。
Health Policy. 2005 Sep 8;73(3):330-8. doi: 10.1016/j.healthpol.2004.12.002. Epub 2005 Jan 12.
10
The impact of health technology assessment reports on decision making in Austria.卫生技术评估报告对奥地利决策的影响。
Int J Technol Assess Health Care. 2012 Jan;28(1):77-84. doi: 10.1017/S0266462311000729. Epub 2012 Jan 11.

引用本文的文献

1
Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe.中东欧的肿瘤孤儿药的卫生技术评估和报销政策。
Orphanet J Rare Dis. 2020 Oct 8;15(1):277. doi: 10.1186/s13023-020-01556-9.
2
Abiraterone acetate and docetaxel with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer in China: an indirect treatment comparison and cost analysis.醋酸阿比特龙与多西他赛联合雄激素剥夺疗法用于中国高负荷转移性激素敏感性前列腺癌的治疗：间接治疗比较与成本分析
Cost Eff Resour Alloc. 2019 Dec 13;17:27. doi: 10.1186/s12962-019-0193-4. eCollection 2019.
3
Reimbursement Legislations and Decision Making for Orphan Drugs in Central and Eastern European Countries.中东欧国家罕见病药物的报销立法与决策
Front Pharmacol. 2019 May 8;10:487. doi: 10.3389/fphar.2019.00487. eCollection 2019.
4
Reimbursement of Orphan Drugs in Europe in Relation to the Type of Authorization by the European Medicines Agency and the Decision Making Based on Health Technology Assessment.欧洲孤儿药报销与欧洲药品管理局的授权类型及基于卫生技术评估的决策之关系
Front Pharmacol. 2018 Nov 12;9:1263. doi: 10.3389/fphar.2018.01263. eCollection 2018.
5
Cold War Legacy in Public and Private Health Spending in Europe.欧洲公共与私人医疗支出中的冷战遗产
Front Public Health. 2018 Aug 6;6:215. doi: 10.3389/fpubh.2018.00215. eCollection 2018.
6
Global health worker salary estimates: an econometric analysis of global earnings data.全球卫生工作者薪资估计：对全球收入数据的计量经济学分析
Cost Eff Resour Alloc. 2018 Mar 9;16:10. doi: 10.1186/s12962-018-0093-z. eCollection 2018.

本文引用的文献

1
The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications.中东欧实施管理准入协议：发现与启示。
Pharmacoeconomics. 2017 Dec;35(12):1271-1285. doi: 10.1007/s40273-017-0559-4.
2
Future and potential spending on health 2015-40: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries.2015-2040 年的卫生未来和潜在支出：卫生发展援助，以及 184 个国家的政府、预付款私人和自费卫生支出。
Lancet. 2017 May 20;389(10083):2005-2030. doi: 10.1016/S0140-6736(17)30873-5. Epub 2017 Apr 19.
3
Evolution and patterns of global health financing 1995-2014: development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries.1995-2014 年全球卫生筹资的演变和格局：184 个国家的卫生发展援助、政府、预付款私人和自费卫生支出。
Lancet. 2017 May 20;389(10083):1981-2004. doi: 10.1016/S0140-6736(17)30874-7. Epub 2017 Apr 19.
4
Evolving Health Expenditure Landscape of the BRICS Nations and Projections to 2025.金砖国家不断演变的卫生支出格局及到2025年的预测
Health Econ. 2017 Jul;26(7):844-852. doi: 10.1002/hec.3406. Epub 2016 Sep 29.
5
Utilisation of the ESMO-MCBS in practice of HTA.欧洲医学肿瘤学会（ESMO）临床效益评分系统（ESMO-MCBS）在卫生技术评估实践中的应用。
Ann Oncol. 2016 Nov;27(11):2134-2136. doi: 10.1093/annonc/mdw297. Epub 2016 Aug 8.
6
Health Economics at the Crossroads of Centuries - From the Past to the Future.世纪之交的健康经济学——从过去到未来。
Front Public Health. 2016 Jun 9;4:115. doi: 10.3389/fpubh.2016.00115. eCollection 2016.
7
Are payers treating orphan drugs differently?支付方对罕见病药物的待遇是否有所不同？
J Mark Access Health Policy. 2014 Jan 15;2. doi: 10.3402/jmahp.v2.23513. eCollection 2014.
8
Time trends in statin utilisation and coronary mortality in Western European countries.西欧国家他汀类药物使用情况及冠状动脉死亡率的时间趋势。
BMJ Open. 2016 Mar 30;6(3):e010500. doi: 10.1136/bmjopen-2015-010500.
9
Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies.商业数据库与行政数据库利用率的差异：对未来卫生经济及跨国研究的启示
Expert Rev Pharmacoecon Outcomes Res. 2016;16(2):149-52. doi: 10.1586/14737167.2016.1158649. Epub 2016 Mar 17.
10
Patient cost sharing and medical expenditures for the Elderly.老年人的患者费用分担与医疗支出。
J Health Econ. 2016 Jan;45:115-30. doi: 10.1016/j.jhealeco.2015.10.005. Epub 2015 Nov 1.